

Sterol carrier protein₂-like activity in rat intestine

Akram Kharroubi, Jeanne A. Wadsworth, Ronald Chanderbhan, P. Wiesenfeld, B. Noland,* T. Scallen,* G. V. Vahouny, and Linda L. Gallo¹

Department of Biochemistry, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, and Department of Biochemistry, University of New Mexico School of Medicine,* Albuquerque, NM 87131

Abstract A sterol carrier protein₂ (SCP₂)-like activity has been demonstrated in rat intestinal mucosal homogenates and in isolated intestinal cells from both crypt and villus zones. The results indicate the presence of a protein with similar molecular weight and antigenicity to that of authentic SCP₂ purified from rat liver cytosol. Like liver SCP₂, mucosal cytosol stimulates pregnenolone production in rat adrenal mitochondria and acyl coenzyme A:cholesterol acyltransferase activity of liver and mucosal microsomes. The distribution of SCP₂-like activity as determined by radioimmunoassay indicates high levels in mitochondria and cytosol and relatively lower levels in microsomes and in brush-border membranes. The widespread distribution of SCP₂-like protein in the intestine is consistent with potential transfer functions in all phases of cholesterol processing.—Kharroubi, A., J. A. Wadsworth, R. Chanderbhan, P. Wiesenfeld, B. Noland, T. Scallen, G. V. Vahouny, and L. L. Gallo. Sterol carrier protein₂-like activity in rat intestine. *J. Lipid Res.* 1988. 29: 287–292.

Supplementary key words ACAT • cholesterol esterification • intestinal cells • liver SCP₂ • subcellular organelles • radioimmunoassay • Western blot

The small intestine receives cholesterol via several routes. Like all tissues studied (1) the intestine synthesizes cholesterol de novo and receives cholesterol from serum lipoproteins (2, 3). Unlike other tissues, the intestine takes up luminal cholesterol from dietary and biliary sources (e.g., 4). Presumably, cholesterol derived from the three sources, to a greater or lesser extent, may be directed along several routes, including: retention to meet cellular requirements; exocytosis into the intestinal lumen; and exocytosis into the lymph as part of a lipoprotein package. Since cholesterol is relatively water-insoluble, transfer proteins may facilitate sterol movement along these pathways. Similar transfer functions of sterol carrier protein have been described in other tissues such as liver (5–7), adrenal (8), and ovary (9). Like intestine, cholesterol turnover in these tissues is high. In the present study, an SCP₂-like protein has been demonstrated in intestine. This protein shares functional and immunological properties with authentic liver SCP₂ and displays the same molecular size.

MATERIALS AND METHODS

Rat liver SCP₂ and anti-SCP₂ IgG

Rat liver SCP₂ was purified to homogeneity as previously reported (5). Antisera were raised in rabbits against SCP₂ electrostatically complexed to phosphorylated bovine serum albumin (BSA) (10). Control IgG and anti-SCP₂ IgG were purified by protein A-Sepharose affinity chromatography (11) and by albumin-Sepharose affinity chromatography. The characteristics and specificity of the anti-SCP₂ IgG have been described (12).

Animals

Male adult Wistar rats (Charles River Breeding Laboratories, Wilmington, MA) were acclimated under a normal light cycle for 2 weeks with free access to laboratory chow (Ralston-Purina Co., St. Louis, MO) and water prior to killing by decapitation.

Reagents

All chemicals and solvents were reagent grade (Fisher Scientific, Silver Spring, MD), unless otherwise indicated.

Preparation and characterization of subcellular organelles and isolated cells

Adrenal mitochondria were prepared as previously described (8). *Liver microsomes and cytosol* were prepared from a 5% homogenate as described by Teerlink et al. (12).

Intestinal subcellular organelles were prepared from a 1% homogenate of mucosa scraped from the proximal small intestine ($\cong 32$ cm). The mucosa was homogenized in iced 0.273 M mannitol containing 5 mM EDTA adjusted to pH 7.4. Nuclei and cell debris were sedimented by cen-

Abbreviations: ACAT, acyl coenzyme A:cholesterol acyltransferase; BSA, bovine serum albumin; IgG immunoglobulin G; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SCP₂, sterol carrier protein₂; DTT, dithiothreitol; RIA, radioimmunoassay; PBS, phosphate-buffered saline.

¹To whom reprint requests should be addressed.

trifugation (Model J21-B) at 1440 *g* for 10 min and washed once under the same conditions. The combined postnuclear supernatants were centrifuged at 6000 *g* for 15 min to collect the mitochondrial fraction, and the 6000 *g* supernatant was centrifuged at 55,000 *g* (Model LL3-50, Beckman Instruments, Fullerton, CA) for 2 hr to sediment the microsomal fraction. The 55,000 *g* supernatant was termed the mucosal cytosol. Organelles were resuspended either in the homogenization solution to give 10–20% suspensions based upon the original wet-weight mucosa or in RIA buffer, described below, as required by the individual methodologies. The concentration of the original homogenates and the centrifugation conditions selected, yielded the highest organelle purity based upon the distribution of standard organelle markers.

Intestinal cells were isolated from the crypt and villus zones of proximal small intestine (\cong 32 cm) as described by Weiser (13). The segment of intestine was washed initially with 150 ml of 0.154 M NaCl containing 1 mM DTT. Then, with buffers A and B as defined (13), the intestinal segment was filled with buffer A, each end was tied, and the segment was placed into a polystyrene flask containing buffer A and incubated for 15 min at 10°C in an oscillating (2 cycles/sec) Dubnoff metabolic shaker. Dislodged cells, designated Fraction 1, were collected by rinsing the segment with 50 ml of buffer A. The segment, with minimal handling, was filled with buffer B incubated for 15 min at 10°C with shaking, drained, and flushed with 50 ml of buffer B. The dislodged cells were designated Fraction 2. The buffer B cycle was repeated six times for periods of 15, 10, 10, 5, 5, 5 min and six additional populations of cells were collected and designated Fractions 3–8. Cells were pelleted by centrifugation at 900 *g* for 5 min. An estimate of cell type in each fraction was assessed with the crypt-zone marker enzyme, thymidine kinase (14), and villus zone marker enzyme, alkaline phosphatase (13). The marker enzymes were assayed in a 10% homogenate (phosphate-buffered saline) of each packed cell pellet. In the individual experiments, the cell pellets were homogenized in the buffer and at the concentration indicated.

Brush border membranes were prepared from rat jejunal mucosa by the method of Kessler et al. (15). The purity of the brush border membranes was assessed by measuring the marker enzymes sucrase and alkaline phosphatase. The specific activity of these enzymes was 20- and 15-fold higher as compared to the whole homogenate. In contrast, recovery of ACAT, succinate dehydrogenase, and DNA in these membranes was less than 0.5% of the total activity. These results were comparable to those of Kessler et al. (15).

Assays

Acyl coenzyme A:cholesterol acyltransferase activity (ACAT) in mucosal and liver microsomes was determined by the rate of incorporation of [$1\text{-}^{14}\text{C}$]oleic acid into cholesteryl ester (16). Siliconized 50-ml glass conical tubes containing 5.1

mM ATP, 512 μM coenzyme A, 5.0 mg of BSA (each from Sigma Chemical Co., St. Louis, MO), 10.5 mM $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 0.2 M potassium phosphate, pH 7.4, 227 mM [$1\text{-}^{14}\text{C}$]oleic acid, 0.4 μCi (57.4 mCi/mmol, Amersham Corp., Arlington Heights, IL) added in 10 μl acetone, and 334 μM cholesterol (Serdary Research Laboratories, London, Ontario) added in 5 μl of dioxane (freshly distilled)–propylene glycol 2:1 (v/v) were preincubated at 37°C for 15 min. The ACAT-catalyzed reaction was initiated by the addition of 80 μl of a 10% microsomal suspension which gave a final incubation volume of 0.55 ml. Digests were incubated at 37°C in an oscillating Dubnoff metabolic shaker, and reactions were terminated by the addition of 20 volumes of chloroform–methanol 2:1 (v/v) (17) either after 3 min or with time over a 15-min period. The 3-min reaction time was determined previously to fall on the linear region of the rate curve. [$1,2\text{-}^3\text{H}$]Cholesteryl oleate (20,000 dpm), prepared and purified by thin-layer chromatography just prior to use as described by others (15, 16, 18, 19), was added to the extraction mixture as the internal standard to correct for procedural losses (not > 10%). Zero-time and buffer controls were included and each assay was run in triplicate. Lipids were extracted according to Folch, Lees, and Sloane Stanley (17). The solvent was evaporated to dryness under nitrogen and the lipid residue was dissolved in hexane. To determine the quantity of [$1\text{-}^{14}\text{C}$]oleic acid incorporated into cholesteryl ester, the lipids were separated on Silica Gel G precoated thin-layer chromatography plates (Uniplates, Analtech, Newark, DE). The silicic acid areas corresponding to cholesteryl esters, as identified with authentic standards (Nuclechek Prep Inc., Elysian, MN) were scraped into counting vials. Radioactivity was measured in a liquid scintillation counter (Model LS-250, Beckman Instruments, Fullerton, CA). The external standard-channels ratio method of quench calibration was used to monitor the dual-labeled samples.

SCP₂-like protein levels and distribution were estimated in subcellular organelles from intestinal mucosa and in isolated intestinal cells by radioimmunoassay (20). Liver SCP₂ was radioiodinated (21) with Bolton-Hunter reagent (Amersham Corp., Arlington Heights, IL) to a specific activity of 20–50 $\mu\text{Ci}/\mu\text{g}$ and the ^{125}I -labeled SCP₂ was assessed as pure based upon migration as a single radioactive band upon SDS-PAGE and autoradiography.

Subcellular organelles from mucosa or isolated intestinal cells were resuspended in RIA buffer (10 mM sodium phosphate, pH 7.2, containing 0.15 M NaCl, 1 $\mu\text{g}/\text{ml}$ leupeptin, 0.1% BSA, and 0.01% Triton X-100) lacking only BSA, sonicated (Branson, Danbury, CT) for 20 sec at cycle 50, and diluted in RIA buffer to give protein concentrations of 0.2–1.0 mg/ml. Anti-SCP₂ IgG was diluted in the same buffer to a concentration (8 $\mu\text{g}/\text{ml}$) that gave 40–50% binding of ^{125}I -labeled SCP₂ in the absence of competing ligand. In polypropylene test tubes, 0.1 ml of

tissue fractions was mixed with 0.1 ml of the diluted anti-SCP₂ IgG and 50 μl of ¹²⁵I-labeled SCP₂ (3–4 × 10⁴ cpm) was then added. The tubes were incubated at 4°C for 24 hr. Antibody-bound ¹²⁵I-labeled SCP₂ was separated from free ¹²⁵I-labeled SCP₂ by overnight precipitation at 4°C with 0.1 ml goat anti-rabbit IgG (1.2 mg/ml) (Cooper Biomedical Inc., Malvern, PA). After dilution with 2 ml of ice-cold RIA buffer, the immunoprecipitate was collected by centrifugation at 2,800 rpm for 40 min (IEC-centrifuge) and the supernatant was decanted. Radioactivity was counted in a Beckman Gamma Counter (Model 5500). The RIA data were analyzed using a logit-log computer routine (22). All assays were carried out in triplicate.

SCP₂-identity in subcellular organelles from intestinal mucosa was substantiated by electrophoretic blotting (20, 23). Organelle suspensions sonicated for 20 sec at cycle 50 and treated with a mixture of 0.4% SDS and 1% 2-mercaptoethanol for 5 min at 90°C were applied to an SDS (0.15%)–polyacrylamide gradient (10–15%) slab gel. The organelle proteins were resolved by electrophoresis (24) and were transferred (23) from the gel to nitrocellulose sheets, 0.45 μm pore size (Bio-Rad Laboratories, Richmond, CA). Nonspecific protein binding sites on the sheet were blocked with 1% BSA contained in 10 mM Tris-HCl and 0.15 M NaCl, pH 7.4, (buffer C) by incubation at room temperature for 30 min.

The nitrocellulose sheets were subjected to a series of treatment and wash cycles performed at room temperature as follows: treated for 90 min with 50 ml (44.5 ng/ml) of either rabbit anti-SCP₂ IgG or rabbit control IgG in buffer C containing 10% horse serum, and washed five times for 5 min each with PBS containing 1% horse serum; treated for 60 min with 50 ml (30 μg/ml) of goat anti-rabbit IgG in buffer C containing 10% horse serum and washed as above; treated for 60 min with 50 ml peroxidase-anti-peroxidase IgG (Cooper Biomedicals, Westchester, PA; 1:2000) in buffer C containing 10% horse serum and washed as above; and treated for 30–60

TABLE 1. Effect of mucosal cytosol on pregnenolone production in adrenal mitochondria

Additions	Pregnenolone Production ng/mg protein per 25 min
None	50.4 ± 2.8 ^a
Mucosal cytosol	200.0 ± 10.6
Liver cytosol	153.0 ± 4.2
Liver SCP ₂	190.0 ± 3.5
Mucosal cytosol + anti-SCP ₂ IgG	50.4 ± 2.8
Mucosal cytosol + control IgG	176.0 ± 15.6

Adrenal mitochondria (2.48 mg protein) were incubated in a 2.0-ml reaction volume for 25 min at 37°C with mucosal cytosol (5.6 mg of protein), liver cytosol (5.6 mg of protein), liver SCP₂ (20 μg), mucosal cytosol (5.6 mg of protein) treated with anti-SCP₂ IgG (28 μg) or control IgG (28 μg). Pregnenolone was measured by RIA (36).

^aMean ± SD; n = 2.

TABLE 2. Effect of mucosal cytosol on mucosal and liver ACAT activity

Additions	ACAT Activity ^a pmol cholesteryl ester/min per mg
Mucosal microsomes	538 ± 38
Mucosal microsomes + mucosal cytosol	550 ± 37 ^b
Liver microsomes	130 ± 10
Liver microsomes + mucosal cytosol	300 ± 21
Mucosal cytosol	1.4 ± 1

Liver and mucosal microsomes and mucosal cytosol were prepared as described under Methods. Each assay contained in a final volume of 0.55 ml: 5.1 mM ATP, 512 μM coenzyme A, 5.0 mg of BSA, 10.5 mM MgCl₂ · 6H₂O, 227 mM [1¹⁴C]oleic acid (0.4 μCi), 334 μM cholesterol, 0.2 M potassium phosphate, pH 7.4, and either microsomal suspension (200 μg of protein) ± mucosal cytosol (6 mg of protein) or mucosal cytosol alone (6.0 mg of protein). Reactions were terminated with time over a 15-min period by addition of 20 volumes of chloroform–methanol 2:1 (v/v). Cholesteryl ester was extracted and analyzed as described under Methods.

^aExpressed as pmol of cholesteryl ester formed/min per mg protein, mean ± SD, n = 2.

^bRepresents a doubling (4 min to 8 min) in time over which initial reaction rate was linear.

sec with the peroxidase substrate mixture, 0.02% diaminobenzidine tetrahydrochloride, 0.02% imidazole (Sigma Chemical Co., St. Louis, MO) and 0.01% H₂O₂ in buffer C without BSA, and then washed with distilled water and dried.

Protein was determined by the method of Lowry et al. (25) with BSA as the standard.

RESULTS

Effect of mucosal cytosol on pregnenolone production

Addition of mucosal cytosol (5.6 mg of protein) to adrenal mitochondria resulted in a fourfold stimulation in pregnenolone production from endogenous cholesterol compared with mitochondria incubated under the same conditions but without added cytosol. The level of the stimulatory effect produced by mucosal cytosol was equivalent to that produced by purified liver SCP₂ (20 μg) and greater than the threefold stimulation produced by the same amount of liver cytosol protein as shown in **Table 1**.

When mucosal cytosol was pretreated with anti-SCP₂ IgG, its stimulatory effect on mitochondrial pregnenolone production was abolished completely, shown in **Table 1**. However, cytosol treated with control IgG was fully stimulatory.

Effect of mucosal cytosol on ACAT activity

The addition of mucosal cytosol to assays for ACAT activity in mucosal and liver microsomes mimicked the stimulatory effect reported earlier for authentic liver SCP₂ (26). As shown in **Table 2**, the addition of mucosal cytosol

to liver microsomes more than doubled the initial rate of ester formation (130 vs. 300 pmol/min per mg of protein). In contrast, the addition of mucosal cytosol to mucosal microsomes, while not altering the initial rate of the ACAT-catalyzed esterification, doubled the time (4 to 8 min, rate curve not shown) that the initial reaction rate was linear. In four other experiments linearity was extended from as little as 2 min to as much as an additional 7 min.

Distribution of SCP₂-like protein in intestinal cells

Consistent with a general role for SCP₂ in cholesterol transport is its presence in villus tip and crypt populations of isolated intestinal cells as shown in **Table 3**. Cell fractions 1 and 2, which were predominantly from the villus zone, and cell fractions 7 and 8, which were predominantly from the crypt zone, contained an average of 650 ng of SCP₂ and 1300 ng of SCP₂ per mg of cell protein, respectively. Such a dual occurrence of SCP₂ permits participation in cholesterol biosynthesis, reported to take place primarily in crypts (27), cholesterol esterification, which occurs in both crypts and villus cells (26–28), and any additional cholesterol transfer function that may occur in both cell types.

Distribution of SCP₂-like protein in intestinal subcellular organelles

SCP₂-like protein was present in the four major subcellular organelles prepared from intestinal mucosa. As shown in **Table 4**, the highest SCP₂-like protein specific activity resided in the mitochondria which was fivefold greater than in nuclei, and seven- to ninefold greater than in microsomes and cytosol. Of the total homogenate SCP₂-like protein, over 70% was equally divided between mitochondria and cytosol, 25% was localized in the nuclei and cell debris, and just 3% was found in the microsomal fraction. The recovery of SCP₂-like protein in the organelles averaged no less than 75% of that measured in the homogenate. The brush border membranes have very low levels of SCP₂-like protein.

TABLE 3. SCP₂-like protein in villus and crypt cells

Fraction	SCP ₂ -like Protein	AP ^a	TK ^a	Protein
	ng/mg	% of total	mg	
1	200	22	0	16
2	1100	22	7	27
7	1700	7	38	31
8	900	0.1	12	5

Fractions 1 and 2 are enriched in villus zone cells, 7 and 8 are enriched in crypt zone cells, and 3–6 are a mixed cell population (not shown). SCP₂-like protein was determined by RIA. The cell isolation procedure, marker enzyme activity assays, and protein determination are described under Methods.

^aAP, alkaline phosphatase; TK, thymidine kinase.

TABLE 4. Distribution of SCP₂-like protein in subcellular organelles from intestinal mucosa

Organelle	SCP ₂ -like Protein	Distribution
	ng/mg protein	%
Experiment 1		
Homogenate	415 ± 81 ^a	
Nuclei and cell debris	279 ± 29	25.3 ± 3.5
Mitochondria	1470 ± 368	34.0 ± 3.1
Microsomes	169 ± 13	3.3 ± 0.02
Cytosol	196 ± 3.0	37.4 ± 0.4
Experiment 2		
Brush border membranes	16.6 ± 3.0 ^b	

Organelles were prepared by ultracentrifugation and their SCP₂-like protein was determined in triplicate by RIA. Organelles (0.1 ml containing 20 to 100 µg of protein) were mixed with anti-SCP₂ IgG (0.1 ml containing 0.8 µg of protein) and 50 µl of ¹²⁵I-labeled SCP₂ (3–4 × 10⁴ cpm). After incubation at 4°C for 24 hr, goat anti-rabbit IgG (0.1 ml containing 120 µg of protein) was added and incubation at 4°C was continued for an additional 24 hr. The immunoprecipitate was collected and radioactivity was monitored. The RIA data were analyzed using a logit-log computer routine.

^aMean ± SD, n = 2.

^bMean ± SD, n = 3.

Electrophoretic blotting analysis for SCP₂-like protein in intestinal subcellular organelles

Of the solubilized proteins in the four major subcellular organelles that were resolved by SDS-PAGE and transferred to nitrocellulose strips, the only protein recognized by anti-SCP₂ IgG displayed the same molecular size as authentic liver SCP₂. This result is shown in **Fig. 1**. The intensity of the stain for SCP₂-like protein in the organelles is consistent with the quantitative distribution for SCP₂-like protein determined by RIA.

DISCUSSION

Numerous low molecular weight proteins function in intracellular lipid transfers (e.g., 29). By performing this role, they facilitate cellular processes dependent upon lipid availability. In particular, SCP₂ and/or SCP₂-like proteins are present in tissues active in cholesterol metabolism (5, 8, 9) and have been shown in the adrenal to transfer cholesterol from cytoplasmic lipid droplets to mitochondria and from the outer to the inner mitochondrial membrane (29); in liver (30, 31) and intestine (26) SCP₂ facilitates ACAT-catalyzed cholesterol esterification; and in liver, SCP₂ participates in cholesterol (5) and bile acid (32) synthesis.

In the current study, an SCP₂-like protein(s) has been detected in rat intestinal mucosa. The original detection of SCP₂-like protein in intestine was based upon the ability of mucosal cytosol to mimic authentic liver SCP₂ in stimulating pregnenolone production in adrenal mitochondria and the subsequent complete loss of this stimu-




Fig. 1. Western blot analysis of SCP₂-like protein in subcellular organelles from intestinal mucosa; A, liver SCP₂ (0.8 μg); B, homogenate; C, nuclei; D, mitochondria; E, microsomes; F, cytosol. Each organelle represents 150 μg of protein.

latory effect when mucosal cytosol was pretreated with anti-SCP₂ IgG. Moreover, mucosal cytosol was stimulatory to ACAT-catalyzed cholesterol esterification in both liver and intestinal microsomes, a reported function of authentic SCP₂ (5, 26). Intestinal SCP₂ on Western blots displayed a molecular size (14,000 daltons) which was indistinguishable from pure liver SCP₂.

When the distribution of mucosal SCP₂-like protein was determined for subcellular organelles, cytosol was shown to contain about 40% (Table 4) of the total. Therefore, one might speculate that SCP₂-like protein functions in the transfer of absorbed (dietary and biliary) cholesterol between its sites of cellular entry and utilization. By comparison, liver nonspecific lipid transfer protein (which is identical to SCP₂) has been shown to facilitate the exchange of cholesterol between brush border membranes and acceptor vesicles (33). Specifically in intestine, since a large amount of absorbed sterol is destined for lipoprotein packaging, a necessity for sterol transfer from the brush border to the site of its obligatory esterification is anticipated. Cholesterol esterase, an intestinal enzyme thought to esterify luminal sources of cholesterol, is localized in the cytosol. However, we were unable to assess the effect of SCP₂-like protein on this activity, since the enzyme assay utilizes bile salts which are known to inactivate SCP₂. In contrast, mucosal ACAT, which esterifies microsomal cholesterol, was stimulated by mucosal cytosol SCP₂-like protein, which presumably delivers exogenous cholesterol to the microsomes. Moreover, in an earlier study (26), authentic liver SCP₂, not only in the presence but also in the absence of added exogenous cholesterol, produced a similar but less dramatic effect on mucosal ACAT which suggests an SCP₂-facilitated movement of an intramicrosomal pool of sterol to the enzyme. A compari-

son of the effects of mucosal cytosol SCP₂-like protein on liver and intestinal microsomal ACAT activity in the presence of exogenous cholesterol reveals an increase in the initial reaction rate in liver and an extension of the initial reaction rate in mucosal microsomes. This suggests that the available endogenous cholesterol is not saturating in the liver system and that mucosal cytosol SCP₂-like protein delivers exogenous cholesterol so that saturation is approached, whereas in the intestine, mucosal cytosol SCP₂-like protein prolongs the supply of cholesterol to the initially substrate-saturated enzyme. This interpretation of the SCP₂-like protein effect is based on the earlier observation (27) that exogenous cholesterol (added in solvent) extends the initial reaction rate of ACAT in mucosal microsomes beyond that seen in its absence but increases the initial reaction rate in liver microsomes (34).

Another microsomal function for SCP₂-like protein may be the stimulation of cholesterol biosynthesis, a reported function of SCP₂ in liver (5). However, the apparent low concentration of SCP₂-like protein in intestinal microsomes (169 ng/mg of protein) relative to liver (2470 ng/mg of protein, unpublished results from this laboratory) speaks against this function unless the protein has the ability to facilitate the synthetic processing without microsomal residence or unless the level of SCP₂ in or associated with microsomes may be dependent upon the cellular demand for cholesterol biosynthesis, i.e., a dynamic process.

The high concentration of SCP₂-like protein in the mitochondria is similar to what is found in the adrenal (20, 35). However, a mucosal function for mitochondrial SCP₂ is not immediately apparent but might be related to its reported phospholipid exchange activity (29).

Not only was SCP₂-like protein associated with several intracellular organelles, but it was also present in an enriched population of either villus or the crypt zone intestinal cells. These varied intracellular and multicellular locations are consistent with a role for SCP₂-like protein in many phases of cholesterol processing in the intestine. ■

This work was supported in part by Public Health Service grants NIH 5 ROI-RR-5359-23 and HL 32982.

Manuscript received 27 April 1987 and in revised form 3 August 1987.

REFERENCES

- Dietschy, J. M., and J. D. Wilson. 1970. Regulation of cholesterol metabolism. *N. Engl. J. Med.* **282**: 1128-1138, 1179-1183, 1241-1249.
- Dietschy, J. M., D. K. Spady, and E. F. Stange. 1983. Quantitative importance of different organs for cholesterol synthesis and low-density lipoprotein degradation. *J. Biochem. Soc. Trans.* **11**: 639-641.
- Suzuki, N., N. Fidge, P. Nestel, and J. Yin. 1983. Interac-

- tion of serum lipoproteins with the intestine. Evidence for specific high density lipoprotein-binding sites on isolated rat intestinal mucosal cells. *J. Lipid Res.* **24**: 253-264.
4. Vahouny, V. G., and C. R. Treadwell. 1968. Cholesterol absorption. In *Handbook of Physiology*, Sec. 6, Vol. 3. C. F. Code and W. Heidel, editors. American Physiological Society, Washington, DC. 1407-1438.
 5. Noland, B. J., R. E. Arebalo, E. Hansbury, and T. J. Scallen. 1980. Purification and properties of sterol carrier protein₂. *J. Biol. Chem.* **255**: 4282-4289.
 6. Poorthuis, B. J. H. M., J. F. C. Glatz, R. Akeroyd, and W. A. Wirtz. 1981. A new high-yield procedure for the purification of the nonspecific phospholipid transfer protein from rat liver. *Biochim. Biophys. Acta.* **665**: 256-261.
 7. Trzaskos, J. M., and J. L. Gaylor. 1983. Cytosolic modulator of activities of microsomal enzymes of cholesterol biosynthesis: purification and characterization of a non-specific lipid-transfer protein. *Biochim. Biophys. Acta.* **751**: 52-65.
 8. Chanderbhan, R., B. J. Noland, T. J. Scallen, and G. V. Vahouny. 1982. Sterol carrier protein₂ delivery of cholesterol from adrenal lipid droplets to mitochondria for pregnenolone synthesis. *J. Biol. Chem.* **257**: 8928-8934.
 9. Chanderbhan, R., T. Tanaka, J. F. Strauss, D. Irwin, B. J. Noland, T. J. Scallen, and G. V. Vahouny. 1983. Evidence for sterol carrier protein₂-like activity in hepatic, adrenal and ovarian cytosol. *Biochem. Biophys. Res. Commun.* **117**: 702-709.
 10. Van Vanakes, H., J. Kaplan, N. Lehrer, and L. Levine. 1966. Immunogenicity of polylysine and polyornithine when complexed to phosphorylated bovine serum albumin. *Immunochemistry.* **3**: 393-402.
 11. Gooding, T. W. 1976. Conjugation of antibodies with fluorochromes: modification to the standard methods. *J. Immunol. Methods.* **13**: 215-226.
 12. Teerlink, T., T. P. Vanderkrift, M. Part, and W. A. Wirtz. 1982. Tissue distribution and subcellular localization of phosphatidylcholine transfer protein in rats as determined by radioimmunoassay. *Biochim. Biophys. Acta.* **713**: 61-67.
 13. Weiser, M. M. 1973. Intestinal epithelial cell surface membrane glycoprotein synthesis. *J. Biol. Chem.* **248**: 2536-2541.
 14. Salser, J. E., and M. E. Balis. 1973. Distribution and regulation of deoxy-thymidine kinase activity in differentiating cells of mammalian intestine. *Cancer Res.* **33**: 1889-1897.
 15. Kessler, M., O. Acuto, C. Storelli, H. Murer, M. Müller, and G. Semenza. 1978. A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of D-glucose and choline transport systems. *Biochim. Biophys. Acta.* **506**: 136-154.
 16. Balasubramanian, S., K. A. Mitropoulos, and S. Vankatesan. 1978. Rat liver acyl CoA:cholesterol acyl transferase. *Eur. J. Biochem.* **90**: 377-383.
 17. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for isolation and purification of total lipids from animal tissues. *J. Biol. Chem.* **226**: 497-509.
 18. Deykin, D., and D. S. Goodman. 1962. The hydrolysis of long-chain fatty acid esters of cholesterol with rat liver enzymes. *J. Biol. Chem.* **237**: 3649-3659.
 19. Gartner, S. L., and G. V. Vahouny. 1972. Effects of epinephrine and 3'5' dibutryl cyclic AMP on perfused rat hearts. *Am. J. Physiol.* **222**: 1121-1124.
 20. Kharroubi, A., R. Chanderbhan, G. Fiskum, B. J. Noland, T. J. Scallen, and G. V. Vahouny. 1986. Distribution of sterol carrier protein₂ (SCP₂) in rat tissues and evidence for slow turnover in liver and adrenal cortex. *Fed. Proc.* **45**: 1025 (Abstract).
 21. Bolton, A. E., and W. M. Hunter. 1973. The labelling of proteins to high specific radioactivities by conjugation to a ¹²⁵I-containing acylating agent. *Biochem. J.* **133**: 529-539.
 22. Rodbard, D., and J. E. Lewald. 1970. Computer analysis of radioligand assay and radioimmunoassay data. *Acta Endocrinol.* **64**: (Suppl. 147): 79-103.
 23. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels in nitrocellulose sheets: procedure and some applications. *Proc. Natl. Acad. Sci. USA.* **76**: 4350-4354.
 24. Irwin, D., and J. D. Dauphinais. 1979. A tissue-specific code based on the abundance of SDS-solubilized proteins. *Anal. Biochem.* **92**: 193-198.
 25. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**: 265-275.
 26. Gallo, L., S. Myers, and G. V. Vahouny. 1984. Rat intestinal acyl coenzyme A:cholesterol acyl transferase properties and localization. *Proc. Soc. Exp. Biol. Med.* **177**: 188-196.
 27. Stange, E. F., K. E. Suckling, and J. M. Dietschy. 1983. Synthesis and coenzyme A-dependent esterification of cholesterol in intestinal epithelium. *J. Biol. Chem.* **258**: 12868-12875.
 28. Field, F. J., A. D. Cooper, and S. K. Erickson. 1982. Regulation of rabbit intestinal acyl coenzyme A:cholesterol acyl transferase in vivo and in vitro. *Gastroenterology.* **83**: 873-880.
 29. Vahouny, G. V., R. Chanderbhan, B. J. Noland, and T. J. Scallen. 1985. Cholesterol ester hydrolase and sterol carrier proteins. *Endocr. Res.* **10**: 473-505.
 30. Gavey, K. L., B. J. Noland, and T. J. Scallen. 1981. The participation of sterol carrier protein₂ in the conversion of cholesterol to cholesterol ester by rat liver microsomes. *J. Biol. Chem.* **256**: 2993-2999.
 31. Poorthuis, B. J. H. M., and K. W. A. Wirtz. 1982. Increased cholesterol esterification in rat liver microsomes by purified non-specific phospholipid protein. *Biochim. Biophys. Acta.* **710**: 99-105.
 32. Seltman, H., W. Diven, M. Rizk, B. J. Noland, R. Chanderbhan, T. J. Scallen, G. Vahouny, and A. Sanghvi. 1985. Regulation of bile-acid synthesis: role of sterol carrier protein₂ in the biosynthesis of 7-hydroxycholesterol. *Biochem. J.* **230**: 19-24.
 33. Bloj, B., and D. B. Zilversmit. 1982. Heterogeneity of rabbit intestinal brush border plasma membrane cholesterol. *J. Biol. Chem.* **257**: 7608-7614.
 34. Gavey, K. L., B. J. Noland, and T. J. Scallen. 1981. The participation of sterol carrier protein₂ in the conversion of cholesterol to cholesterol ester by rat liver microsomes. *J. Biol. Chem.* **256**: 2993-2999.
 35. Chanderbhan, R. F., A. T. Kharroubi, B. J. Noland, T. J. Scallen, and G. V. Vahouny. 1986. Sterol carrier protein₂: further evidence for its role in adrenal steroidogenesis. *Endocr. Res.* **12**: 351-370.
 36. Johnson, L. R., A. Ruhmann-Wennhold, and D. H. Nelson. 1973. The in vivo effect of ACTH on utilization of reducing energy for pregnenolone synthesis by adrenal mitochondria. *Ann. N.Y. Acad. Sci.* **212**: 307-318.